Hope seems to be on its way to mesothelioma patients. Good news
because the European Commission has just granted Verastem, Inc.’s VS-6063 the orphan
status.
According to News-Medical.net, Verastem, Inc., has been working
hard to discover and develop drugs that will treat cancer aiming at cancer stem
cells.
VS-6063’s orphan designation only serves to encourage the
development of the drug, which will provide benefit to patients with
mesothelioma cancer, as well as other diseases.
The drug-maker wants to begin “the randomized, double-blind,
placebo controlled trial of VS-6063 in mesothelioma” within this year.
"We are pleased that the EMA recognizes the significant
unmet medical need in mesothelioma," said Christoph Westphal, M.D., Ph.D.,
Verastem Chairman and Chief Executive Officer. "This orphan drug
designation provides us with a number of benefits in the development of
VS-6063."

